Related Experiment Video

Updated: Aug 6, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth

Peter M van Koetsveld1, Giovanni Vitale, Wouter W de Herder

  • 1Department of Internal Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands.

The Journal of Clinical Endocrinology and Metabolism
|August 17, 2006
PubMed
Abstract

Insights

Type I interferons (IFN) show promise for treating adrenocortical carcinoma (ACC). IFN-beta1a demonstrated superior potency over IFN-alpha2b in suppressing ACC cell growth by inducing apoptosis and cell cycle arrest in vitro.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options.
  • Surgery is the primary treatment for ACC, but novel therapeutic strategies are needed for metastatic disease.
  • Type I interferons (IFNs) have demonstrated tumor-suppressive capabilities in various human cancers.

Purpose of the Study:

  • To evaluate the in vitro tumor-suppressive effects of type I interferons (IFN)-alpha2b and IFN-beta on human ACC cell lines.
  • To compare the potency of IFN-alpha2b and IFN-beta in inhibiting ACC cell proliferation and inducing cell death.
  • To elucidate the underlying molecular mechanisms of IFN-mediated anti-ACC effects.

Main Methods:

  • Human ACC cell lines (H295 and SW13) were treated with IFN-alpha2b and IFN-beta1a.
  • Quantitative RT-PCR and immunocytochemistry were used to assess type I IFN receptor (IFNAR) expression.
  • Cell proliferation, apoptosis, cell cycle progression, and IGF-II mRNA expression were analyzed.

Main Results:

  • H295 and SW13 cells express functional type I IFN receptors (IFNAR-1 and IFNAR-2c).
  • IFN-beta1a exhibited significantly greater potency than IFN-alpha2b in inhibiting ACC cell growth, inducing apoptosis, and causing S-phase arrest in H295 cells.
  • IFN-beta1a suppressed IGF-II mRNA expression in H295 cells, while IFN-alpha2b did not.

Conclusions:

  • IFN-beta1a is a more potent suppressor of ACC cell proliferation in vitro compared to IFN-alpha2b.
  • The anti-tumor mechanisms involve apoptosis induction and cell cycle arrest.
  • Further in vivo studies are warranted to assess IFN-beta1a's therapeutic potential in ACC.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.